Jeremie H Estepp

List of Publications by Year
in descending order

65	1,013	567281 15	501196 28
papers	citations	h-index	g-index

69	69	69	1306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	27.0	117
2	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nature Immunology, 2022, 23, 781-790.	14.5	116
3	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics, 2016, 138, .	2.1	71
4	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	4.1	66
5	Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host and Microbe, 2022, 30, 83-96.e4.	11.0	64
6	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	1.5	57
7	Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 2031-2036.	1.5	51
8	Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. British Journal of Haematology, 2013, 161, 402-405.	2.5	40
9	Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. JMIR MHealth and UHealth, 2020, 8, e14884.	3.7	38
10	Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica, 2019, 104, e385-e387.	3.5	26
11	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. MSphere, 2022, 7, e0017922.	2.9	25
12	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. Cancer Research, 2021, 81, 2556-2565.	0.9	24
13	The Edoxaban Hokusai VTE PEDIATRICS Study: An openâ€label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 886-892.	2.3	23
14	Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11Âyears. Pediatric Blood and Cancer, 2022, 69, e29716.	1.5	21
15	Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. American Journal of Hematology, 2019, 94, E27-E29.	4.1	19
16	The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. Pediatric Blood and Cancer, 2012, 59, 105-109.	1.5	15
17	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306.	2.0	14
18	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Advances, 2021, 5, 2839-2851.	5.2	14

#	Article	IF	Citations
19	An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. Microbiology Spectrum, 2021, 9, e0105921.	3.0	14
20	Voxelotor (<scp>GBT</scp>440), a firstâ€inâ€class hemoglobin oxygenâ€affinity modulator, has promising and reassuring preclinical and clinical data. American Journal of Hematology, 2018, 93, 326-329.	4.1	13
21	Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia. Journal of Physical Education and Sports Management, 2018, 4, a003384.	1.2	12
22	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. Open Forum Infectious Diseases, 2021, 8, ofab420.	0.9	12
23	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood, 2020, 136, 19-20.	1.4	12
24	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. Clinical Infectious Diseases, 2022, 75, e705-e714.	5.8	10
25	A reanalysis of pain crises data from the pivotal l-glutamine in sickle cell disease trial. Contemporary Clinical Trials, 2021, 110, 106546.	1.8	9
26	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	3.5	9
27	Hydroxycarbamide in children with sickle cell anaemia after firstâ€dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure. British Journal of Clinical Pharmacology, 2018, 84, 1478-1485.	2.4	8
28	The association of mediastinal mass in the formation of thrombi in pediatric patients with nonâ€lymphoblastic lymphomas. Pediatric Blood and Cancer, 2020, 67, e28057.	1.5	7
29	Cancer and Tumor-Associated Childhood Stroke: Results From the International Pediatric Stroke Study. Pediatric Neurology, 2020, 111, 59-65.	2.1	7
30	Neurocognitive functioning in preschool children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29531.	1.5	7
31	What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study. British Journal of Haematology, 2021, 194, 463-468.	2.5	6
32	The clinical severity of hemoglobin S/Black (^AÎ³Î²)⁰â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26596.	1.5	5
33	Vasoâ€occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease. Pediatric Blood and Cancer, 2018, 65, e27435.	1.5	5
34	Screening for Obstructive Sleep Apnea in Children With Sickle Cell Disease: A Pilot Study. Laryngoscope, 2021, 131, E1022-E1028.	2.0	5
35	Future Perspectives for the Treatment of Sickle Cell Anemia. , 2016, , 399-429.		4
36	Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. Journal of Surgical Research, 2019, 242, 336-341.	1.6	4

#	Article	IF	Citations
37	Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia. Experimental Biology and Medicine, 2021, 246, 2473-2479.	2.4	4
38	An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood, 2020, 136, 19-20.	1.4	4
39	Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia. Blood, 2014, 124, 85-85.	1.4	4
40	MAGiC: VOC remains but kids with SCA appear. Blood, 2015, 126, 1637-1638.	1.4	3
41	Safe Use of Lowâ€“Molecular-weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures. Journal of Pediatric Hematology/Oncology, 2017, 39, 596-601.	0.6	3
42	Developmental screening of threeâ€yearâ€old children with sickle cell disease compared to controls. British Journal of Haematology, 2021, 195, 621-628.	2.5	3
43	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	1.4	3
44	Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children with Sickle Cell Disease: A Prospective Trial. Blood, 2017, 130, 760-760.	1.4	3
45	Fetal hemoglobin modulates neurocognitive performance in sickle cell anemiaâœ°,âœ°âœ°. Current Research in Translational Medicine, 2022, 70, 103335.	1.8	3
46	Strategies to increase access to basic sickle cell disease care in low- and middle-income countries. Expert Review of Hematology, 2022, 15, 333-344.	2.2	3
47	Risk for deep venous thrombosis in pediatric cancer patients undergoing surgery. Journal of Pediatric Surgery, 2021, 56, 2360-2363.	1.6	2
48	Data Access and Interactive Visualization of Whole Genome Sequence of Sickle Cell Patients within the St. Jude Cloud. Blood, 2018, 132, 723-723.	1.4	2
49	GMEPS: a fast and efficient likelihood approach for genome-wide mediation analysis under extreme phenotype sequencing. Statistical Applications in Genetics and Molecular Biology, 2022, 21, .	0.6	2
50	Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia on St. Jude Total Therapy Studies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S180.	0.4	1
51	A metaâ€analysis of toxicities related to hydroxycarbamide dosing strategies. EJHaem, 2020, 1, 235-238.	1.0	1
52	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	2.5	1
53	Children with Sickle Cell Anemia and APOL1 Gene Variants Develop Albuminuria Early in Life. Blood, 2018, 132, 2377-2377.	1.4	1
54	Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease. Pharmaceutics, 2022, 14, 1065.	4.5	1

#	Article	IF	Citations
55	The Impact of Hydroxyurea Therapy on the Prevalence of Retinopathy in a Pediatric Sickle Cell Cohort. Blood, 2011, 118, 1057-1057.	1.4	0
56	Escalating Doses Of Hydroxyurea In Very Young Children With Sickle Cell Anemia. Blood, 2013, 122, 978-978.	1.4	0
57	Prognostic Factors for Hospitalization of Children with Sickle Cell Anemia Treated with Hydroxyurea at Maximum Tolerated Dose. Blood, 2015, 126, 2177-2177.	1.4	0
58	Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea. Blood, 2016, 128, 1314-1314.	1.4	0
59	Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the Î²-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production. Blood, 2016, 128, 125-125.	1.4	0
60	Fetal Hemoglobin Level during Hydroxyurea Therapy Varies By Neighborhood. Blood, 2018, 132, 2221-2221.	1.4	0
61	Insulin-like Growth Factor Binding Protein-3 (IGFBP3) Induces Fetal Hemoglobin in Hematopoietic Stem and Progenitor Cells from Patients with Sickle Cell Anemia. Blood, 2018, 132, 722-722.	1.4	0
62	Association of Thrombospondin-1 Gene Polymorphism with Elevated Tricuspid Regurgitant Velocity in Sickle Cell Anemia. Blood, 2021, 138, 2027-2027.	1.4	0
63	Social Determinants of Health and Neurocognitive Functioning in Sickle Cell Disease. Blood, 2021, 138, 2030-2030.	1.4	0
64	Food Deserts Are Associated with Acute Care Utilization Among Preschool Children with Sickle Cell Disease. Blood, 2020, 136, 19-19.	1.4	0
65	Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease. Blood, 2020, 136, 23-24.	1.4	0